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ABSTRACT
Sexually transmitted infections (STI) in HIV-infected people are of increasing
concern. We estimated STI prevalence and sexual healthcare seeking behaviour in 224
sexually active HIV-infected people, including men who have sex with men (MSM,
n = 112), heterosexual men (n = 65) and women (n = 47). Laboratory-diagnosed
bacterial STI were more common in MSM (Chlamydia trachomatis 10.7%; 95%
CI 6.2, 18.0%, lymphogranuloma venereum 0.9%; 95% CI 0.1, 6.2%, Neisseria
gonorrhoeae 2.7%; 95% CI 0.9, 8.0%, syphilis seroconversion 5.4%; 95% CI 2.0,
11.3%) than heterosexual men (gonorrhoea 1.5%; 95% CI 0.2, 10.3%) or women
(no acute infections). Combined rates of laboratory-diagnosed and self-reported
bacterial STI in the year before the study were: MSM (27.7%; 95% CI 21.1, 36.7%);
heterosexual men (1.5%; 95% CI 0.2, 10.3%); and women (6.4%; 95% CI 2.1,
21.0%). Antibodies to hepatitis C virus were least common in MSM. Antibodies to
herpes simplex type 2 virus were least common in heterosexual men. Most MSM, but
not heterosexual men or women, agreed that STI testing should be offered every year.
In this study, combined rates of bacterial STI in MSM were high; a regular assessment
of sexual health would allow those at risk of STI to be offered testing, treatment and
partner management.
Subjects Epidemiology, HIV, Infectious Diseases
Keywords Hepatitis B, Hepatitis C, Herpes simplex type 2, HIV infection, Sexual health, Sexually
transmitted infections, Sexually transmitted diseases, Chlamydia trachomatis,
Neisseria gonorrhoeae, Syphilis
INTRODUCTION
Sexually transmitted infections (STI) are important health risks for people living with HIV
infection in the era of combination antiretroviral therapy (cART) (Fakoya et al., 2007).
Surveillance reports of syphilis, gonorrhoea and chlamydia have risen during the 2000s,
particularly in men who have sex with men (MSM) (Bundesamt fu¨r Gesundheit, 2013;
Centers for Disease Control and Prevention, 2014). In addition, there have been outbreaks
of STI which were previously rare, like lymphogranuloma venereum (LGV) (Bundesamt
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fu¨r Gesundheit, 2005; Bremer et al., 2006; Ward et al., 2007) and hepatitis C (Wandeler et al.,
2012; Yaphe et al., 2012) in HIV positive MSM.
Regular testing for STI is recommended in some countries as part of routine follow up
for all people with HIV infection (California STD Controllers Association and California
Coalition of Local AIDS Directors, 2001; Fakoya et al., 2007). But the levels of STI at which
regular testing in people with HIV infection is worthwhile are unclear (Rieg et al., 2008).
Estimating the frequency of STI can be difficult because cohort studies are challenging
(Jin et al., 2007b; Rieg et al., 2008) and cross-sectional studies miss episodes diagnosed in
different settings at different times. Jin et al. (2007a) tried to overcome this challenge by
combining diagnoses made at yearly study visits with self-reported diagnoses in the past
year in a cohort of HIV negative MSM.
There are no guidelines for regular STI testing in HIV-infected people in Switzerland.
The Swiss HIV Cohort Study (SHCS) (2010) provides regular follow up and care for about
7500 people with HIV infection in Switzerland, of whom 30% are women and 35% are
assumed to have acquired HIV through sex between men. The aim of this study was to
inform decisions about the need for regular STI screening in HIV-infected people in
Switzerland. Specific objectives were to estimate the prevalence of bacterial and viral STI
and patterns of sexual health care seeking behaviour in sexually active HIV-infected MSM,
heterosexual men and women.
METHODS
We enrolled patients attending routine visits to the outpatient HIV clinic of the Bern
University Hospital, Switzerland from 20.05.2009 to 28.05.2010 when a clinic physician
was available to explain the study. Patients were eligible for inclusion if they were aged
18 years or older, had confirmed HIV infection, were enrolled in the SHCS, had had sexual
intercourse in the last 12 months and gave written consent. The doctor administered a
standardised questionnaire (in German, French or English) that asked about recent sexual
partner history, previous STI and case management. All patients underwent a standard
physical examination and gave a first-catch urine specimen and a blood sample. Additional
specimens were taken from the throat and/or rectum from patients who reported having
had receptive oral or anal sex in the last year. Whilst waiting for their blood test, patients
were asked to complete a supplementary questionnaire, which they posted into a box in
the clinic or returned later by mail. There were additional questions about satisfaction
with management for previous STI and preferences for future sexual health services.
All questionnaires were labelled with only a unique identification number to protect
confidentiality. Additional epidemiological, patient history and cART data were derived
from the SHCS database. The Canton of Bern Ethical Committee approved the study
protocol (application number 026/09).
Specimens were tested in the laboratory of the University Institute of Infectious
Diseases, according to manufacturers’ instructions. First catch urine specimens were
tested by polymerase chain reaction for Chlamydia trachomatis (COBAS TaqMan CT
Test v2.0, Roche Diagnostics, Rotkreuz, Switzerland) and Neisseria gonorrhoeae (opa-based
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real-time PCR assay, TIB Molbiol, Berlin, Germany, on the COBAS TaqMan Analyzer,
Roche Diagnostics); tests that were positive for C. trachomatis were further examined and
typed for LGV strains (ompA-based in-house assay, Institute for Medical & Molecular
Diagnostics, Zu¨rich, Switzerland). Blood was tested for herpes simplex type 2 (HSV-2)
antibodies (HerpeSelect 2 ELISA IgG, Focus Diagnostics, Cypress, CA, USA). Results of
the most recent serological tests for syphilis, hepatitis B and hepatitis C infections were
obtained from the patient’s SHCS clinical record.
Patients with a diagnosed STI received their results by telephone from the treating
physician and received antibiotic treatment, where appropriate, from the clinic. Uncompli-
cated chlamydia was treated with azithromycin 1 g as a single dose or doxycycline 100 mg
twice daily for seven days, LGV doxycycline 100 mg twice daily for 21 days. Gonorrhoea
was treated with ceftriaxone 250 mg by intramuscular injection. Partner management
was discussed at the same visit and partners were contacted by the study doctor, with the
agreement of the patient. Outcomes of partner notification were asked at the next follow
up visit.
Statistical analysis
Our study plan assumed that 700 HIV-infected patients would visit the outpatient clinic
in one year and 50% would be enrolled. Based on published studies, if the prevalence of
chlamydia or gonorrhoea was 10% (35/350), 95% confidence intervals (95% CI) would be
7.0% to 13.6% (Phipps et al., 2005; Jin et al., 2007b; Dang et al., 2009).
We conducted descriptive univariable analyses separately amongst MSM, heterosexual
men and women and made statistical comparisons between groups using chi-squared tests.
In all analyses heterosexual women and women who have sex with women were considered
as a single group because of the small number; no woman who has sex with women was
diagnosed with an STI. In each group we estimated the point prevalence of STI (with 95%
CI) amongst sexually active HIV-positive people tested using the number with a positive
test result at the study visit as a percentage of all participants. We used the method of
Jin et al. (2007a) to estimate a one-year rate of diagnosed bacterial STI by adding study-
diagnosed infections and self-reported infections in the previous year. We did not do mul-
tivariable analyses because the study was not designed to investigate risk factors for STI.
RESULTS
We enrolled 232 HIV-infected patients during the study period. Study clinicians assessed
698 patients for eligibility (Fig. 1). Of these, 250 (36%) did not fulfil the inclusion criteria
and 216 (31%) declined to participate. Amongst the enrolled patients (232/448, 52%
of those eligible), eight were excluded from analysis because their records could not be
linked to an SHCS number. Amongst the 224 included study participants there were 177
men (112 men who have sex with men and 65 heterosexual men) and 47 women (44
heterosexual and 3 women who have sex with women).
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Figure 1 Flow chart of included and excluded patients.
Characteristics, STI Risks and symptoms amongst participants
Table 1 shows the social and demographic characteristics of study participants. Their mean
age was 44 years (standard deviation, SD 9.1 years), almost all had received antiretroviral
therapy and most had an undetectable viral load on the day of the study visit. Compared
with all patients under active follow up in Bern (The Swiss HIV Cohort Study, 2010) patients
in this study were less likely to be female (20% vs. 35%).
Reported sexual behaviours differed by sex and sexual orientation (Table 2). Almost
70% of MSM reported two or more sexual partners in the last 12 months compared
with 21.5% of heterosexual men and 10.7% of women (p < 0.001). MSM were more
likely than heterosexual men or women to report having casual sexual partners alone or
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Table 1 Characteristics of study participants at enrolment (N = 224).
Characteristic N (%)
Sex, sexual orientation Men who have sex with men 112 (50.0)
Heterosexual men 65 (29.1)
Heterosexual women 44 (19.6)
Women who have sex with women 3 (1.3)
Route of HIV acquisition Sex between men 108 (48.2)
Heterosexual sex 77 (34.4)
Injection drug use 26 (11.6)
Other or unknown 13 (5.8)
Country of birth Switzerland 113 (50.4)
Other 35 (15.6)
Missing 76 (33.9)
Age in years, mean (standard deviation) 44.4 (9.1) na
CD4 count on day of visit, cells/µ l, mean (standard deviation) 525.9 (280) na
Viral load <40 copies/mL Yes, received antiretroviral therapy 154 (68.8)
Yes, never received antiretroviral therapy 2 (0.9)
No, ever received antiretroviral therapy 16 (7.1)
No, never received antiretroviral therapy 37 (16.5)
Missing 15 (6.7)
Notes.
na, not applicable; MSM, men who have sex with men; STI, sexually transmitted infection.
both casual and regular partners (p < 0.001). Amongst participants reporting any casual
partners,≥50% reported consistent condom use, including three quarters of MSM who
reported receptive anal sex. Consistent condom use for receptive anal sex was also reported
by almost three quarters of MSM reporting any regular partners. For vaginal sex, most
heterosexual men, but not women, reported consistent condom use.
Diagnosed sexually transmitted and sexually transmissible
infections
Few participants (11/224, 4.9%) reported any symptoms associated with STI on the day of
study enrolment (see Table 2).
Bacterial infections
Sixteen men had positive test results for N. gonorrhoeae, C. trachomatis, or both at the
study visit. The prevalence of each STI (% and 95% CI) on the day of study enrolment
is shown in Table 3. Three MSM (2.7%, 95% CI 0.9, 8.0%) had gonococcal infection
(two rectal, one pharyngeal). One heterosexual man had pharyngeal gonorrhoea; he did
not report any male sexual partners and there was no confirmatory specimen for culture
before treatment. All 13 chlamydia-infected participants were MSM; 12 (10.7%, 95%
CI 6.2, 18.0%) had C. trachomatis serovars D-K detected (five urethral, six rectal, one
pharyngeal) and one had a rectal LGV serovar 2b. One MSM had both rectal gonorrhoea
and chlamydia. There were 45 participants with positive serologic tests for syphilis with the
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Table 2 Sexual behaviours reported by patient to physician (N = 224).
MSM Heterosexual men Women P value
Symptoms and sexual partnerships N = 112 (%) N = 65 (%) N = 47 (%)
Any STI symptoms on day of visit
Yes 7 (6.4) 3 (4.6) 1 (2.1) 0.562
No 102 (91.1) 62 (95.4) 45 (97.8)
Not reported 3 (2.7) 0 (0) 1 (2.1)
Total number of sexual partners
in past year
1 34 (30.4) 51 (78.5) 42 (89.4) <0.001
2–4 23 (20.5) 11 (16.9) 3 (6.4)
5 55 (49.1) 3 (4.6) 2 (4.3)
Sexual partnership type(s)
Casual partners only 44 (39.3) 14 (21.5) 2 (4.3) <0.001
Both regular and casual partners 34 (30.4) 3 (4.6) 4 (8.5)
Regular partners only 34 (30.4) 48 (73.8) 41 (87.2)
Sexual practices, any casual partnersa N = 78 (%) N = 17 (%) N = 6 (%)
Receptive anal intercourse
Yes, consistent condom use 46 (59.0) 0 (0) 3 (50.0) <0.001
Yes, no consistent condom use 14 (18.0) 0 (0) 0 (0)
No or not reported 18 (23.0) 17 (100) 3 (50.0)
Insertive anal intercourse
Yes, consistent condom use 37 (47.4) 1 (5.9) 0 (0) <0.001
Yes, no consistent condom use 17 (21.8) 1 (5.9) 0 (0)
No or not reported 24 (30.8) 15 (88.2) 6 (100)
Vaginal intercourse
Yes, consistent condom use 4 (5.1) 14 (82.4) 2 (33.3) <0.001
Yes, no consistent condom use 0 (0) 2 (11.8) 1 16.7)
No or not reported 74 (94.9) 1 (5.9) 3 (50.0)
Sexual practices, any regular partnersb N = 68 (%) N = 51 (%) N = 45 (%)
Receptive anal intercourse
Yes, consistent condom use 37 (54.4) 0 (0) 1 (2.2) <0.001
Yes, no consistent condom use 14 (20.6) 0 (0) 0 (0)
No or not reported 17 (25.0) 51 (100) 44 (97.8)
Insertive anal intercourse
Yes, consistent condom use 31 (45.6) 0 (0) 0 (0) <0.001
Yes, no consistent condom use 8 (11.8) 1 (2.0) 0 (0)
No or not reported 29 (42.7) 50 (98.0) 45 (100)
Vaginal intercourse
Yes, consistent condom use 3 (4.4) 36 (70.6) 24 (53.3) <0.001
Yes, no consistent condom use 1 (1.5) 14 (27.5) 17 (37.8)
No or not reported 64 (94.1) 1 (1.9) 4 (8.9)
Notes.
MSM, men who have sex with men; STI, sexually transmitted infection.
a Number with any casual partners is sum of those with only casual and those with both casual and regular partners.
b Number with any regular partners is sum of those with only regular and those with both casual and regular partners.
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Table 3 Laboratory diagnosed sexually transmitted infections (n= 224). Numbers in italics show the distribution of infections by site.
Infection MSM,
N = 112
Heterosexual men,
N = 65
Women,
N = 47
P value
na % (95% CI) n % (95% CI) n % (95% CI)
Chlamydia, serovars D-K 12 10.7 (6.2, 18.0) 0 – 0 – 0.002
Urethral 5 0 0
Rectal 6 0 0
Pharyngeal 1 0 0
LGV, rectal 1 0.9 (0.1, 6.2) 0 – 0 – 0.606
Gonorrhoea 3 2.7 (0.9, 8.0) 1 1.5 (0.2, 10.3) 0 – 0.499
Urethral 0 0 0
Rectal 2 0 0
Pharyngeal 1 1 0
Syphilisb
Any positive serologic test 39 34.8 (26.5, 44.2) 1 1.5 (0.2, 10.3) 5 10.6 (4.5, 23.3) <0.001
Seroconversion during study period 6 5.4 (2.0, 11.3) 0 – 0 – 0.046
HSV-2 58 51.8 (39.1, 57.5) 23 35.4 (24.7, 47.8) 28 59.6 (45.0, 72.6) 0.028
Hepatitis C, antibody positivec 7 6.3 (3.0, 12.6) 21 32.3 (22.0, 44.6) 10 21.3 (11.8, 35.3) <0.001
Hepatitis Bd 0.117
sAg or eAg positive 2 1.8 (0.4, 6.9) 6 9.2 (4.2, 19.2) 2 4.3 (1.1, 15.6)
Core antibody positive 46 41.1 (32.3, 50.5) 19 29.2 (19.4, 41.5) 21 44.7 (31.2, 59.1)
Surface antibody positive,
core antibody negative
27 24.1 (17.0, 33.0) 15 23.1 (14.4, 34.9) 13 27.7 (16.7, 42.1)
Non-immune 28 25.0 (17.8, 33.9) 23 35.4 (24.7, 47.8) 10 21.3 (11.8, 35.3)
Notes.
a One MSM had both chlamydia and gonorrhoea.
b Serologic tests done at baseline (Treponema pallidum haemagglutination assay, TPHA) and yearly thereafter, with follow up tests done as clinically indicated.
c No result available for 11/112 MSM, 3/65 heterosexual men, 1/47 women.
d No result available for 9/112 MSM, 2/65 heterosexual men, 1/47 women.
highest estimated prevalence amongst MSM (p < 0.001). Amongst MSM, six (5.4%, 95%
CI 2.9, 11.3%) had newly reactive serological tests for syphilis during the study period.
Viral infections
Viral infections were diagnosed serologically (Table 3); no participant with HSV-2
antibodies reported genital ulceration on the day of the study visit. HSV-2 infection
was common in all groups of participants with more than half of MSM and women,
and a third of heterosexual men (p = 0.028), having antibodies detected. In contrast,
antibodies to hepatitis C were more common in heterosexual men and in women than in
MSM (p < 0.001). Amongst patients with no recent history of injection drug use, more
heterosexual men (7/46, 15.2%) and women (6/43, 14.0%) than MSM (4/109, 3.7%) had
antibodies to hepatitis C (p= 0.038). Amongst those who acquired HIV through injection
drug use, almost all had antibodies to hepatitis C (MSM, 3/3; heterosexual men 14/19;
women 4/4, p= 0.523). Exposure to hepatitis B virus was common in all groups. A slightly
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Table 4 Cumulative one year rate of laboratory confirmed and self-reported sexually transmitted infection diagnoses.
MSM, N = 112 Heterosexual men, N = 65 Women, N = 47
Study
diagnosis
Interval Cumulative Study
diagnosis
Interval Cumulative Study
diagnosis
Interval Cumulative
na % (95% CI) na % (95% CI) na % (95% CI)
Chlamydia, any
serovarb
13 5 16.1 (10.3, 24.1) 0 0 – 0 2 4.3 (1.1, 15.6)
Gonorrhoea, any site 3 2 4.5 (1.9, 10.3) 1 0 1.5 (0.2, 10.3) 0 0 –
Syphilisc 6 10 14.3 (8.9, 22.1) 0 0 – 0 1 2.1 (0.3, 13.8)
Total number of
patients with
any bacterial STId
31 27.7 (21.1, 36.7) 1 1.5 (0.2, 10.3) 3 6.4 (2.1, 21.0)
Notes.
LGV, lymphogranuloma venereum; STI, sexually transmitted infection.
a Numbers of patients with infections diagnosed at study visit taken from Table 3.
b The question asked about chlamydia infection and did not distinguish between urogenital and LGV serovars or by clinical site of infection, so these have been grouped
together.
c Study diagnoses include only patients with serological evidence of new infection. Interval diagnoses include all those who said they had been diagnosed with syphilis in
the previous year. Not asked if new or old diagnosis.
d Total is the number of individual patients with either a study visit or interval diagnosis of any chlamydial infection, gonorrhoea or syphilis.
higher percentage of heterosexual men (35.4%) than MSM (25.0%) or women (21.3%)
were non-immune.
Cumulative diagnoses of acute sexually transmitted infections
Participants reported diagnoses, from a list of named STI, in the one year interval before
the study. Overall, 19% (21/112) of MSM and 13% (6/47) of women reported having
been diagnosed with any STI. Table 4 shows the one-year cumulative rate of bacterial STI,
estimated as the sum of study diagnosed and self-reported (interval) infections as reported
by Jin et al. (2007a). The one-year cumulative rate of any chlamydial infection at any site
was 16.1% (95% CI 10.3, 24.1%) in MSM and 4.3% (95% CI 1.1, 15.6%) in women and
of gonorrhoea the rate was 4.5% (95% CI 1.9, 10.3%) in MSM and 1.5% (0.2, 10.3%)
in heterosexual men. Additional self-reported interval STI included five MSM and one
woman with genital warts, two MSM and three heterosexual men with genital herpes, one
woman with pubic lice and one woman with scabies.
STI testing and healthcare seeking behaviour
Amongst MSM and women, a substantial percentage reported that they had been tested
for STI in the 12 months before the study visit (see Table 5). Most patients who were
tested reported that this had been done at an HIV outpatient clinic. The most common
alternative source of STI care was private gynaecologists for women. A majority of
participants in all groups reported that they felt comfortable speaking about sexual health
and STI related issues with doctors in the HIV clinic. Opinions about the role of the
STI clinic in offering regular STI testing differed between groups, however. About three
quarters of MSM agreed that STI testing should be offered routinely every year. A sizeable
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Table 5 Previous sexually transmitted infection testing and management, reported by patients (n= 182).
MSMa
N = 95
Heterosexual men,a
N = 48
Womena,
N = 39
P value
n (%) n (%) n (%)
Have you been tested for any STI in the last 12 months? 0.015
Yes, tested positive for any STI 21 (22.1) 4 (8.3) 6 (15.4)
Yes, tested negative for all 29 (30.5) 6 (12.5) 7 (18.0)
No, not tested 39 (41.1) 33 (68.8) 20 (51.3)
Not known 6 (6.3) 5 (10.4) 6 (15.4)
Where have tests for STI been done? 0.006
HIV outpatient clinic 45 (47.4) 8 (16.7) 9 (23.1)
STI specialist 0 (0) 1 (2.1) 0 (0)
General practitioner 4 (4.2) 1 (2.1) 0 (0)
Gynaecologist 1 (1.1) 0 (0) 4 (10.3)
Not tested or not known 45 (47.4) 38 (79.2) 26 (66.7)
Can you talk about sexual health and STI at the HIV clinic? 0.336
Yes 68 (71.6) 31 (64.6) 23 (59.0)
No 23 (24.2) 15 (31.3) 14 (35.9)
No response 4 (4.2) 2 (4.2) 2 (5.1)
Should STI testing be done at the HIV outpatient clinic? <0.001
Yes, regularly 69 (72.6) 17 (35.4) 16 (41.0)
Yes, but only if I have symptoms 13 (13.7) 10 (20.8) 3 (7.7)
Yes, but only if I have been at risk 5 (5.3) 9 (18.8) 7 (18.0)
No 6 (6.3) 10 (20.8) 12 (30.8)
No response 2 (2.1) 2 (4.2) 1 (2.6)
Notes.
MSM, men who have sex with men; STI, sexually transmitted infection.
a Not all participants returned a questionnaire; no responses from 17/112 MSM, 17/65 heterosexual men, 8/47 women.
minority of heterosexual men (10/48, 21%) and women (12/39, 31%) thought that STI
tests should not be offered at HIV outpatient clinics.
DISCUSSION
Summary of main findings
In this cross-sectional study of patients attending routine HIV outpatient clinics who
reported having had sexual intercourse in the past year, the prevalence of laboratory
diagnosed bacterial STI was higher in MSM than heterosexual men or women. The rate
of bacterial STI in MSM and women increased when self-reported infections in the year
before the study visit were combined with study diagnosed infections. Antibodies to HCV
were least common in MSM. Antibodies to HSV-2 were least common in heterosexual
men. Most MSM, but not heterosexual men or women, agreed that STI testing should be
offered every year.
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Strengths and weaknesses of study methods
Strengths of this study are that it enrolled a prospective sample of both male and female
patients and used standardised methods of data collection and validated laboratory tests
in a single centre. The number of patients assessed for eligibility matched the sample
size calculation but the precision of STI prevalence estimates was reduced because fewer
patients than planned were eligible; nearly a third of patients assessed reported that they
had not had sexual intercourse in the previous year. We might have missed STI diagnoses
if they were, in fact, sexually active but we think this unlikely, especially since so few STI
were diagnosed in the enrolled heterosexual men and women. The number of participants
enrolled was comparable to that of HIV-infected patients in other single centre studies
(Bachmann et al., 2005; Stolte et al., 2006; Rieg et al., 2008) with a participation rate
amongst eligible patients of about 50%. To minimise disruption to the clinic during
the study period, we did not collect data about those who declined participation so our
interpretation assumes that non-participation was not associated with the probability of
having an STI diagnosis.
Comparison with other studies
We did not find any other prospective studies comparing the prevalence of laboratory-
detected STI in MSM, heterosexual men and women. Given the role of STI in driving
HIV transmission (Cohen, 2012), the number of prospective studies examining STI in any
groups of HIV-infected people in the era of cART is modest. One global review found
37 studies of any design in any population published from 2000 to 2010 (Kalichman,
Pellowski & Turner, 2011). Only seven of these studies examined acute bacterial STI in
prospective systematic samples of HIV-infected patients in Europe, Australia or North
America (Whittington et al., 2002; Bachmann et al., 2005; Phipps et al., 2005; Stolte et al.,
2006; Jin et al., 2007b; Rieg et al., 2008; Dang et al., 2009) and only one included women
(Phipps et al., 2005). In MSM in our study the estimated point prevalences of chlamydia
(11% any site), LGV (1%), gonorrhoea (3% any site), newly reactive syphilis serology (5%)
were consistent with: another study in Switzerland (11% anorectal chlamydia serovars
D-K, 1% LGV) (Dang et al., 2009); Australia (3% rectal or urethral gonorrhoea, 8% rectal
or urethral chlamydia) (Jin et al., 2007b); and North America (14% gonorrhoea, chlamydia
or newly reactive syphilis serology) (Rieg et al., 2008), (10% gonorrhoea or chlamydia at
any site) (Whittington et al., 2002). Other recent studies have estimated a higher prevalence
of rectal chlamydia (Stolte et al., 2006). Amongst women, one study in San Francisco found
no chlamydia but pharyngeal gonorrhoea in 6% (3/46) women (Phipps et al., 2005). Two
studies that included men did not stratify their findings by sexual orientation (Bachmann
et al., 2005; Phipps et al., 2005).
The cumulative rate of STI in our study, combining new diagnoses and self-reported
chlamydia, gonorrhoea and syphilis in the preceding year (28%; 21%–37%) was higher
than the combined rates for HIV-negative MSM estimated by Jin et al. (2007a). The
prevalence of STI has also been found to be higher in HIV-positive than HIV-negative
MSM in Australia (Jin et al., 2007b), Germany (Dudareva-Vizule et al., 2013) and the USA
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(Whittington et al., 2002). Even if some syphilis infections reported by MSM in our study
were old or treated episodes (Thurnheer et al., 2010), the combined rate in our study was
consistent with the findings of a prospective study of 212 MSM in two urban clinics in
the USA who were tested at baseline, six and 12 months; 28% (95% CI 22%–34%) tested
positive for chlamydia or gonorrhoea at any site or had newly reactive syphilis serology
(Rieg et al., 2008). Amongst women, all chlamydia infections were self-reported and
the combined prevalence of 4% is compatible with that of sexually active women tested
opportunistically in non-HIV clinic settings (Adams et al., 2004).
Serological evidence of HSV-2 infection was common in all groups in our study and
was asymptomatic in most people, as in other studies (Romanowski et al., 2009). Hepatitis
C was the only infection that was more common in heterosexual men and women than
in MSM, even amongst those who reported no recent history of injection drug use. This
pattern of seroprevalence has been observed before in the SHCS as a whole (Rauch et
al., 2005) and probably reflects infections that resulted from past injection drug use or
other parenteral exposures because heterosexual transmission of hepatitis C is uncommon
(Bresters et al., 1993). The exponential increase in sexually transmitted hepatitis C infection
in MSM in Switzerland (Wandeler et al., 2012) began at around the time that we conducted
our study. A substantial minority of patients had no serologic immunity against hepatitis
B, but we could not differentiate between people who were unvaccinated, had not
seroconverted, which is common in people with HIV infection, or in whom titres had
waned over time.
Interpretation and implications for STI testing
The point prevalences of asymptomatic STI in sexually active HIV-infected MSM in
our study population were similar to those in countries that recommend regular testing
(California STD Controllers Association and California Coalition of Local AIDS Directors,
2001; Fakoya et al., 2007). STI testing in the routine clinic setting was feasible, most MSM
in our study stated that they could discuss sexual health in the HIV outpatient clinic and
most would accept regular STI testing. Sampling from the rectum and pharynx of MSM
was important because more than half of the chlamydia and gonorrhoea infections were
detected at these sites (Dudareva-Vizule et al., 2013). STI prevalences in HIV-infected
heterosexual men and women in our study were more similar to those in HIV-uninfected
people. Although these patient groups are less willing than MSM to endorse routine STI
testing, a sexual health assessment offers opportunities for offering hepatitis B vaccination
to non-immune individuals, early treatment for hepatitis C (Taylor et al., 2014) and to find
out about the reproductive health needs of HIV-infected women (Fakoya et al., 2007).
A major reason for testing and treating STI in HIV-infected people is to reduce the
transmissibility of HIV. Diagnosis and treatment of asymptomatic bacterial STI has
benefits for the individual if accompanied by information about infections and their
prevention for patients and their sexual partners and if partners also receive treatment to
prevent re-infection. Specific information for MSM about the risks of STI if they practise
serosorting might be required (Marcus, Schmidt &Hamouda, 2011). Detecting and treating
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asymptomatic pharyngeal and rectal gonococcal infections might help to delay the spread
of antimicrobial resistance, especially if antimicrobial susceptibility testing allows the
prescription of appropriate antibiotic regimens (Low et al., 2014). When assessing sexual
health in the HIV clinic, patients should be asked specifically about oral and anal sex
without condom use so that all potential sites of infection can be sampled.
Population level benefits are less clear. There are no randomised controlled trials of
the effects on HIV transmission of diagnosing and treating STI in HIV-positive MSM but
a large impact is unlikely because most new HIV infections in MSM are thought to be
acquired from people who are unaware that they are HIV-infected (van Sighem et al., 2012).
In summary, guidelines about STI testing amongst HIV-infected people should be based
on local knowledge about STI prevalence in women and men, and their risk of exposure.
Combined prevalence rates of bacterial STI in MSM in our patient population were high
and further studies should be done to assess generalizability to, and the need for guidance
for, Switzerland as a whole. A regular assessment of sexual health in HIV-infected people,
including a sexual history, would allow those at risk of STI to be offered testing, treatment
and partner management.
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